{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:54:55Z","timestamp":1787586895783,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013355","name":"University at Buffalo Center for Protein Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008209","name":"University at Buffalo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007258","name":"State University of New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dmd.2025.100167","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T07:20:04Z","timestamp":1758698404000},"page":"100167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8880-8718","authenticated-orcid":false,"given":"Devam A.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mfonabasi E.","family":"Ette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0440","authenticated-orcid":false,"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bdd.2338","article-title":"Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: advances, challenges, and future perspectives","volume":"44","author":"Goto","year":"2023","journal-title":"Biopharm Drug Dispos"},{"issue":"35","key":"10.1016\/j.dmd.2025.100167_bib2","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.1111671108","article-title":"Membrane tension leads the way","volume":"108","author":"Keren","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.dmd.2025.100167_bib3","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.1021\/acsnano.1c05099","article-title":"Delivery of oligonucleotide therapeutics: chemical modifications, lipid nanoparticles, and extracellular vesicles","volume":"15","author":"Bost","year":"2021","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.dmd.2025.100167_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbamcr.2005.06.002","article-title":"Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers","volume":"1745","author":"Kirkham","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.dmd.2025.100167_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/nat.2018.0727","article-title":"Intracellular trafficking and endosomal release of oligonucleotides: what we know and what we don\u2019t","volume":"28","author":"Juliano","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.dmd.2025.100167_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2014.03.034","article-title":"Endosome maturation, transport and functions","volume":"31","author":"Scott","year":"2014","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100167_bib7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the design of (nano)formulations for delivery of antisense oligonucleotides and small interfering RNA: focus on the central nervous system","volume":"18","author":"Mendon\u00e7a","year":"2021","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.dmd.2025.100167_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10928-021-09761-0","article-title":"A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration","volume":"48","author":"Monine","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.dmd.2025.100167_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.dmd.2025.100167_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"10.1016\/j.dmd.2025.100167_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-014-9398-5","article-title":"Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice","volume":"42","author":"Shimizu","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"10.1016\/j.dmd.2025.100167_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","article-title":"A translational platform PBPK model for antibody disposition in the brain","volume":"46","author":"Chang","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmd.2025.100167_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.121.000805","article-title":"Minimal physiologically based pharmacokinetic-pharmacodynamic (mPBPK-PD) model of GalNAc-conjugated siRNA disposition and gene silencing in preclinical species and humans","volume":"379","author":"Ayyar","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.dmd.2025.100167_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/psp4.12598","article-title":"Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: a case study with anti-BCMA CAR-T","volume":"10","author":"Singh","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl\u2013modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.dmd.2025.100167_bib19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"issue":"10063","key":"10.1016\/j.dmd.2025.100167_bib20","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dmd.2025.100167_bib21","author":"Rohatgi"},{"issue":"6","key":"10.1016\/j.dmd.2025.100167_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","article-title":"Applications of minimal physiologically-based pharmacokinetic models","volume":"39","author":"Cao","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"10.1016\/j.dmd.2025.100167_bib23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10928-013-9332-2","article-title":"Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"40","author":"Cao","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12987-018-0113-6","article-title":"Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood\u2013brain barrier","volume":"15","author":"Hladky","year":"2018","journal-title":"Fluids Barriers CNS"},{"issue":"6","key":"10.1016\/j.dmd.2025.100167_bib25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10928-021-09776-7","article-title":"Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases","volume":"48","author":"Bloomingdale","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"10.1016\/j.dmd.2025.100167_bib26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/psp4.12250","article-title":"Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model","volume":"6","author":"Yamamoto","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100167_bib27","series-title":"Barr's the Human Nervous System: An Anatomical Viewpoint","author":"Kiernan","year":"2009"},{"issue":"7","key":"10.1016\/j.dmd.2025.100167_bib28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12987-016-0040-3","article-title":"Fluid and ion transfer across the blood-brain and blood-cerebrospinal fluid barriers; a comparative account of mechanisms and roles","volume":"13","author":"Hladky","year":"2016","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10.1016\/j.dmd.2025.100167_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3171\/2011.4.SPINE10543","article-title":"Blood supply and vascular reactivity of the spinal cord under normal and pathological conditions","volume":"15","author":"Martirosyan","year":"2011","journal-title":"J Neurosurg Spine"},{"issue":"2","key":"10.1016\/j.dmd.2025.100167_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1302\/0301-620X.56B2.225","article-title":"The blood supply of the spinal cord. A critical vascular zone in spinal surgery","volume":"56","author":"Dommisse","year":"1974","journal-title":"J Bone Joint Surg Br"},{"issue":"12","key":"10.1016\/j.dmd.2025.100167_bib32","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1021\/js980171q","article-title":"Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena","volume":"87","author":"Sharma","year":"1998","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.dmd.2025.100167_bib33","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100167_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.121.000751","article-title":"Antisense oligonucleotide in vitro protein binding determination in plasma, brain, and cerebral spinal fluid using hybridization LC-MS\/MS","volume":"50","author":"Guimaraes","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100167_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1148\/radiology.184.3.1509061","article-title":"US measurement of the subarachnoid space in infants: normal values","volume":"184","author":"Libicher","year":"1992","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.dmd.2025.100167_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"Marino","year":"2008","journal-title":"J Theor Biol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100167_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002916","article-title":"Spartan: a comprehensive tool for understanding uncertainty in simulations of biological systems","volume":"9","author":"Alden","year":"2013","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100167_bib38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/psp4.13001","article-title":"Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma","volume":"12","author":"Yamamoto","year":"2023","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100167_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10928-019-09639-2","article-title":"Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics","volume":"46","author":"Li","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"10.1016\/j.dmd.2025.100167_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10928-021-09772-x","article-title":"Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice","volume":"48","author":"Li","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmd.2025.100167_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pr.119.018101","article-title":"Transitioning from basic toward systems pharmacodynamic models: lessons from corticosteroids","volume":"72","author":"Ayyar","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmd.2025.100167_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1454785","article-title":"A quantitative systems pharmacology (QSP) platform for preclinical to clinical translation of in-vivo CRISPR-Cas therapy","volume":"15","author":"Desai","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:57:19Z","timestamp":1763755039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625094760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0090955625094760"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100167","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100167"}}